API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.sciencedaily.com/releases/2021/09/210907110650.htm#:~:text=Four%20independent%20studies%20published%20in,first%20study%20on%20the%20therapy
http://www.pharmafile.com/news/527670/abbvie-shuts-down-rova-t-development-first-line-advanced-small-cell-lung-cancer-followin
https://www.biospace.com/article/abbvie-cuts-178-stemcentrx-employees-months-after-rova-t-failure/
https://www.reuters.com/article/us-abbvie-stemcentrx-write-down/abbvie-to-record-4-billion-impairment-charges-on-stemcentrx-assets-idUSKCN1OY212
https://endpts.com/remember-that-mega-blockbuster-valuation-abbvie-assigned-to-rova-t-its-starting-to-vanish-quietly/
https://endpts.com/after-blueprinting-rd-hub-abbvie-dishes-out-105m-for-cd39-pact-with-tizonas-new-ceo-from-roche/
https://endpts.com/asco18-abbvie-convinces-one-top-analyst-that-its-6b-megablockbuster-rova-t-is-worthless/
https://www.biospace.com/article/abbvie-s-upadacitinib-looks-good-in-arthritis-trial-rova-t-looks-worse-in-lung-cancer/